Mallinckrodt Patent-Cliff Exposure & CMS Drug Spending Portfolio
Mallinckrodt (St. Louis, MO): 15 reconciled FDA prescription therapies, $1.25B 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | St. Louis, MO |
| Reconciled FDA Portfolio Therapies | 15 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2036-01-01 |
| 2024 CMS Total Public Spend | $1.25B |
| 2024 Medicare Part D Spend | $1.06B |
| 2024 Medicaid Spend | $188.6M |
| California HCAI SB 17 Filings | 8 WAC filings (max 26.4% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Mallinckrodt across sibling Meru public-data platforms.